IL6 and adult-onset Still disease: The present study confirms the results recently proposed by Alexeeva et al. (21) regarding the effective role of CAN in 46 patients with sJIA previously administered the IL-6 inhibitor tocilizumab, extending the concept to the whole spectrum of Still’s disease (both sJIA and AOSD) and confirming the results, regardless of the biologic agents previously used.